Efficacy and safety of pralsetinib in multiple endocrine neoplasia type 2-associated pheochromocytoma: a case report
Open Access
- 29 January 2026
- journal article
- Published by SAGE Publications in Therapeutic Advances in Endocrinology and Metabolism
- Vol. 17
Abstract
A 34-year-old male developed bilateral recurrent pheochromocytomas 10 years after laparoscopic adrenal-sparing surgery for pheochromocytomas. Based on his clinical manifestations and germline REarranged during Transfection (RET) variant, the patient was ultimately diagnosed with multiple endocrine neoplasia type 2B. Based on drug susceptibility testing results from organoid-guided precision therapy, the patient underwent secondary adrenalectomy for the right lesion and received oral pralsetinib to control the left ones. Over 16 months of pralsetinib therapy, we found that the patient achieved sustained therapeutic benefits, specifically characterized by symptomatic relief, significant reduction in hormone levels, and shrinkage of the left adrenal masses. These findings indicate that pralsetinib is effective and safe for treating pheochromocytomas associated with RET missense mutation, but further clinical practices are warranted to confirm its efficacy and safety profile.Keywords
Funding Information
- the National High Level Hospital Clinical Research Funding (2024IR32)
This publication has 23 references indexed in Scilit:
- Hereditary and Sporadic Pheochromocytoma: Comparison of Imaging, Clinical, and Laboratory FeaturesAmerican Journal of Roentgenology, 2022
- Novel RET Fusion RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant PheochromocytomaJCO Precision Oncology, 2021
- Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial ManifestationsEndocrine Pathology, 2021
- Pralsetinib: First ApprovalDrugs, 2020
- MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectivesEndocrine, 2020
- An overview of 20 years of genetic studies in pheochromocytoma and paragangliomaBest Practice & Research Clinical Endocrinology & Metabolism, 2020
- Precision Targeted Therapy with BLU-667 for RET-Driven CancersCancer Discovery, 2018
- Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic reviewEuropean Journal of Internal Medicine, 2018
- MANAGEMENT OF ENDOCRINE DISEASE: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysisEuropean Journal of Endocrinology, 2016
- Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paragangliomaHuman Molecular Genetics, 2011